Our dominant T cell receptor (TCR) technology is a genetic approach developed to optimize the expression and function of TCRs.

For tumor targets expressed intracellularly, we first isolate TCRs that recognize peptides that are presented by MHC class I molecules on the surface of cancer cells. The isolated TCRs are then modified and introduced into T cells to redirect them to kill tumor cells expressing the targets of interest.